Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2240PDF: 1769HTML: 821 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2893PDF: 1042HTML: 5631 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3461PDF: 1320HTML: 2300Fi.1 Gritti.Rambaldi: 221 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2174PDF: 1953HTML: 520 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3618PDF: 1255HTML: 5089Incidence age-standardized rates for HL across the Mediterranean basin: 224 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3462PDF: 2302HTML: 23465Untitled: 219Untitled: 233Untitled: 245 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3322PDF: 1491HTML: 5960Fig1-Ag-Pil: 248Ag-Pil Fig.2: 249 -
CLINICAL ASPECTS OF UNCOMPLICATED AND SEVERE MALARIA
8176PDF: 4355HTML: 7526 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1628PDF: 1075HTML: 418 -
-
CRYOGLOBULIN TEST AND CRYOGLOBULINEMIA HEPATITIS C-VIRUS RELATED
4022PDF: 1337HTML: 2493 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1442HTML: 627PDF: 863 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4528PDF: 1755HTML: 1157 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4514PDF: 1664HTML: 4226Tables and Images: 251 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2602PDF: 868HTML: 9051Efremov 1: 248Efremov 2: 211 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1318PDF: 1060HTML: 401 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4049PDF: 1075HTML: 3890Untitled: 184Cneo. Fig.1: 121Untitled: 113Untitled: 141Untitled: 146 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7759PDF: 2462HTML: 2102Table 1.: 234Table 2.: 243Table 3.: 226Table 4.: 219 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3420PDF: 2008HTML: 7569 -
APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
2639PDF: 999HTML: 15128 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2314PDF: 911HTML: 2010Fig 1 Rossi: 208 -
EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF PEDIATRIC COVID-19 IN THE TERTIARY CARE SYSTEM IN THAILAND: COMPARATIVE DELTA AND PRE-DELTA ERA Pediatric COVID-19 in Thailand during pre-Delta and Delta era
1125PDF: 614HTML: 282 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2239PDF: 1645HTML: 402 -
-
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9251PDF: 6157HTML: 88023Fig.1b: 205Fig.1c: 211Fig.2a: 198Fig.2b: 194Fig.4: 216Fig.2c: 198Fig.3: 200Tab.1: 250Tab.2: 228Tab.3: 210Tab.4: 244Fig1a: 206 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1920PDF: 849HTML: 250 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3126PDF: 900HTML: 7293Kost Fig1: 204Kost Fig 2: 193Kost Fig3: 196Kost Fig 4: 208Kost Fig5: 207Kost fig 6: 193 -
-
PERIPHERAL NERVOUS SYSTEM INVOLVEMENT IN LYMPHOPROLIFERATIVE DISORDERS
1817PDF: 898HTML: 448Fig1: 252Fig.2: 266Fig. 3: 203Fig. 5: 214Fig. 4: 238 -
-
BIOLOGY OF HUMAN MALARIA PLASMODIA INCLUDING PLASMODIUM KNOWLESI
5427PDF: 2843HTML: 30382Antinori Tables 1,2,3: 374 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1858PDF: 585HTML: 356







